The wild type protein,
transthyretin (TTR), and over 120 genetic
TTR variants are amyloidogenic and cause, respectively, sporadic and
hereditary systemic TTR amyloidosis. The homotetrameric TTR contains
two identical thyroxine binding pockets, occupation of which by specific
ligands can inhibit TTR amyloidogenesis in vitro. Ligand binding stabilizes
the tetramer, inhibiting its proteolytic cleavage and its dissociation.
Here, we show with solution-state NMR that ligand binding induces
long-distance conformational changes in the TTR that have not previously
been detected by X-ray crystallography, consistently with the inhibition
of the cleavage of the DE loop. The NMR findings, coupled with surface
plasmon resonance measurements, have identified dynamic exchange processes
underlying the negative cooperativity of binding of “monovalent”
ligand tafamidis. In contrast, mds84, our prototypic “bivalent”
ligand, which is a more potent stabilizer of TTR in vitro that occupies
both thyroxine pockets and the intramolecular channel between them,
has greater structural effects.